Get the Stockscreener App
4.65
6.41%
0.28
Pre-market:
4.55
-0.10
-2.15%
Lexeo Therapeutics Inc stock is traded at $4.65, with a volume of 2.46M.
It is up +6.41% in the last 24 hours and down -8.64% over the past month.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
See More
Previous Close:
$4.37
Open:
$4.555
24h Volume:
2.46M
Relative Volume:
2.85
Market Cap:
$365.13M
Revenue:
$531.00K
Net Income/Loss:
$-99.96M
P/E Ratio:
-2.1214
EPS:
-2.1919
Net Cash Flow:
$-98.96M
1W Performance:
+10.45%
1M Performance:
-8.64%
6M Performance:
-52.36%
1Y Performance:
+18.02%
1-Day Range:
$4.51
$5.04
1-Week Range:
$4.03
$5.04
52-Week Range:
$3.60
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc
Sector
Industry
Phone
(212) 547-9879
Address
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
4.65 | 365.13M | 531.00K | -99.96M | -98.96M | -2.1919 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Raymond James | Strong Buy |
| Nov-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-15-25 | Initiated | Guggenheim | Buy |
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Jun-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-28-23 | Initiated | Chardan Capital Markets | Buy |
| Nov-28-23 | Initiated | JP Morgan | Overweight |
| Nov-28-23 | Initiated | Leerink Partners | Outperform |
| Nov-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-28-23 | Initiated | Stifel | Buy |
View All
Lexeo Therapeutics Inc Stock (LXEO) Latest News
Why is Lexeo Therapeutics stock gaining Monday? - MSN
Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst CallSlideshow (NASDAQ:LXEO) 2026-06-15 - Seeking Alpha
LXEO: Pivotal LX2006 trial in FA finalized, aiming for accelerated approval with strong early data - TradingView
Why Is Lexeo Therapeutics Stock Gaining Monday? - Benzinga
Lexeo finalizes pivotal trial design for gene therapy LX2006 By Investing.com - Investing.com South Africa
LXEO: Pivotal LX2006 trial in FA to start, targeting LVMI reduction with accelerated approval path - TradingView
Lexeo finalizes pivotal trial design for gene therapy LX2006 - Investing.com UK
2 Stocks To Watch Today Following Clinical Trial Updates - RTTNews
Lexeo Therapeutics (LXEO) Advances Gene Therapy Trial for Friedr - GuruFocus
Lexeo Therapeutics Finalizes SUNRISE-FA 2 Pivotal Trial Protocol And Statistical Analysis Plan For LX2006 Gene Therapy In Friedreich Ataxia - marketscreener.com
Lexeo Advances Pivotal LX2006 Trial for FA Cardiomyopathy - TipRanks
Lexeo finalizes SUNRISE-FA 2 pivotal design for LX2006; topline data due 2H 2027, BLA targeted 1H 2028 - TradingView
Lexeo Therapeutics Announces Regulatory Update And Registrational Trial Design For LX2006 Gene Therapy In Friedreich Ataxia - TradingView
LXEO: Pivotal trial for LX2006 in Friedreich ataxia set for Q2 2026, targeting BLA in 2028 - TradingView
LXEO: Pivotal LX2006 study set for Q2 2026, aiming for accelerated approval and BLA in 1H 2028 - TradingView
Lexeo Therapeutics (Nasdaq: LXEO) maps LX2006 pivotal trial, 2027 data and 2028 BLA bid - Stock Titan
Gene therapy trial aims to tackle Friedreich ataxia heart damage - Stock Titan
Lexeo Therapeutics Announces Regulatory Update and - GlobeNewswire
LEXEO THERAPEUTICS INC (LXEO) Stock Chart - ChartMill
Lexeo Therapeutics (LXEO) Edges Higher, Holds Above Key Support After Modest GainPairs Trade - newsline.com
Cantor Fitzgerald Initiates Coverage of Lexeo Therapeutics (LXEO) with Overweight Recommendation - MSN
LXEO News | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation - Sahm
Lexeo Therapeutics (LXEO) Slips 2.29% as Stock Tests Key Support LevelsRSI Overbought Alerts - The Legal Advocate
Lexeo Therapeutics Q1 2026 Earnings: EPS Beat on Lower Operating CostsProfit Announcement - Newser
Lexeo Therapeutics (LXEO) Sees Mild Gains as Stock Holds Above Key SupportATR Trailing Stop - Newser
Top Executive Makes Notable Move in Lexeo Therapeutics Stock - TipRanks
Lexeo (LXEO) COO sells 1,302 shares in tax-related stock sale - Stock Titan
Lexeo Therapeutics (LXEO) CEO sells 3,342 shares in tax-related RSU transaction - Stock Titan
Lexeo Therapeutics (LXEO) Climbs +10.49% — Resistance at $5.20 in Focus 2026-05-20Retail Driven Moves - Newser
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - Caledonian Record
LXEO (NASDAQ:LXEO) Rule 144 notice: 3,342 vested shares; prior sale 10,173 - Stock Titan
LXEO (NASDAQ: LXEO) lists restricted stock vesting; Form 144 shows past sale - Stock Titan
LXEO (NASDAQ: LXEO) insider sale notice — 1,595 vested shares - Stock Titan
4 spaces primed for the next wave of gene therapies - BioSpace
Paradigm BioCapital holds 6.18M Lexeo shares (LXEO); 8.3% stake reported - Stock Titan
Balyasny groups disclose 7.18M shares in Lexeo Therapeutics (LXEO) - Stock Titan
TradingKey - TradingKey
Lexeo Therapeutics, Inc. (LXEO) Eps Diluted (TTM) - Zacks Investment Research
Lexeo Therapeutics Price Target Maintained With a $17.00/Share by Chardan Capital - Moomoo
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Lexeo Therapeutics Is Maintained at Buy by Chardan Capital - Moomoo
Stifel Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Cuts Target Price to $17 - Moomoo
Chardan Capital Reaffirms "Buy" Rating for Lexeo Therapeutics (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics, Inc. Q1 2026 10-Q Report: Financial Results, Forward-Looking Statements, and Key Disclosures - Minichart
Why Lexeo Therapeutics (LXEO) looks attractive at current levels (Parabolic) 2026-05-11Community Sell Signals - newser.com
Lexeo Therapeutics Reports Q1 2026 Results, Advances Cardiac Gene Therapy Pipeline, and Awaits FDA Feedback on Pivotal Trial - Minichart
Raymond James reiterates Strong Buy on Lexeo stock, $25 target By Investing.com - Investing.com Canada
Lexeo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lexeo Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Lexeo Highlights Q1 Progress Advancing Cardiac Gene Therapies - TipRanks
Lexeo Therapeutics Inc Stock (LXEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexeo Therapeutics Inc Stock (LXEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Townsend Richard Nolan | Chief Executive Officer |
May 18 '26 |
Sale |
5.06 |
3,342 |
16,927 |
336,764 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):